RGENRepligen Corporation

$7B

Q2 2024 Earnings

Healthcare Medical - Instruments & Supplies

Income Statement

Revenue

$159M-0.2% YoY

Gross Profit

$73M46.2% margin

Operating Income

$7M4.7% margin

Net Income

$6M3.6% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$35M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$876M

Stockholders' Equity

$2.0B

Cash & Equivalents

$809M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$159M	$159M	-0.2%
Gross Profit	$73M	$80M	-8.2%
Operating Income	$7M	$19M	-61.4%
Net Income	$6M	$20M	-71.1%

Revenue Segments

Product

$154M100%

Royalty

$35,0000%

RGEN Q2 2024 Earnings — Repligen Corporation Revenue & Financial Results | Market Cap Arena